Wogonin Reverses the Drug Resistance of Chronic Myelogenous Leukemia Cells to Imatinib Through CXCL12-CXCR4/7 Axis in Bone Marrow Microenvironment

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Nov 4

PMID 33145265

Citations 5

Authors

Hanbo Cao

Yuan Gao

Ruixuan Wang

Qinglong Guo

Hui Hui

Affiliations

Soon will be listed here.

Abstract

Background: In the current study, chronic myeloid leukemia (CML) cells (K562 and KU812) co-cultured with human bone marrow stromal cells (BMSCs) were significantly less sensitive to imatinib (IM). The activation of the CXCL12-CXCR4/7 axis plays an important role in the protective effect of the bone marrow microenvironment (BME) on CML cells. The aim of this study was to investigate whether Wogonin could increase the sensitivity of CML cells to IM when they were co-cultured with BME and explore its underlying mechanism.

Methods: A model of CML cells co-cultured with BMSCs was applied . Flow cytometric, western blotting, immunofluorescence, and RT-PCR assays were used to explore the protective effects of BME on CML cells.

Results: The results showed that Wogonin could reverse the resistance of CML cells to IM under co-culture conditions by inhibiting Transforming growth factor-β (TGF-β) secretion in the BME, preventing the translocation of Smad4 into nucleus and subsequently reducing the expression of CXCR4 and CXCR7 in CML cells. Moreover, the reverse effect of Wogonin was demonstrated by inhibiting the activation of CXCL12-CXCR4/7 axis via restraining the TGF-β/Smad4/Id3 pathway . studies also showed that Wogonin decreased the expression of CXCR4 and CXCR7 in mice bone marrow with low systemic toxicity, and the mechanism was consistent with the study.

Conclusions: Wogonin increases the sensitivity of CML cells to IM in BME by controlling the TGF-β/Smad4/Id3 pathway and decreasing the expression of CXCR4 and CXCR7. These results co-supported the point that Wogonin could be a potential candidate of reversal agents on treatment of IM-resistant CML.

Citing Articles

GL-V9 induce apoptosis of CML cells via MAPK signaling pathway.

Jiang F, Xue Y, Zhang Q, Ma T, Li Y, Yu X Heliyon. 2024; 10(14):e34030.

PMID: 39100445 PMC: 11295560. DOI: 10.1016/j.heliyon.2024.e34030.

On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.

Wang X, Wang Y, Chen J, Wang Q, Liu Z, Yin Y Sci Rep. 2024; 14(1):10114.

PMID: 38698063 PMC: 11065882. DOI: 10.1038/s41598-024-60859-0.

Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis.

Liu X, Peng X, Cen S, Yang C, Ma Z, Shi X Front Pharmacol. 2023; 14:1129662.

PMID: 36909174 PMC: 9992170. DOI: 10.3389/fphar.2023.1129662.

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.

Bao S, Darvishi M, Amin A, Al-Haideri M, Patra I, Kashikova K J Cancer Res Clin Oncol. 2023; 149(10):7945-7968.

PMID: 36905421 DOI: 10.1007/s00432-022-04444-w.

Wogonin attenuates the pathogenicity of Streptococcus pneumoniae by double-target inhibition of Pneumolysin and Sortase A.

Gu K, Ding L, Wang Z, Sun Y, Sun X, Yang W J Cell Mol Med. 2023; 27(4):563-575.

PMID: 36747468 PMC: 9930429. DOI: 10.1111/jcmm.17684.

References

Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z . A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203(9):2201-13. PMC: 2118398. DOI: 10.1084/jem.20052144. View

Cortes J, Nicolini F, Wetzler M, Lipton J, Akard L, Craig A . Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk. 2013; 13(5):584-91. PMC: 3775895. DOI: 10.1016/j.clml.2013.03.020. View

Ma L, Shan Y, Bai R, Xue L, Eide C, Ou J . A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014; 6(252):252ra121. PMC: 4162097. DOI: 10.1126/scitranslmed.3009073. View

Weisberg E, Azab A, Manley P, Kung A, Christie A, Bronson R . Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2011; 26(5):985-90. PMC: 4124489. DOI: 10.1038/leu.2011.360. View

Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu Y . Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005; 37(3):265-74. DOI: 10.1038/ng1521. View

Vianello F, Villanova F, Tisato V, Lymperi S, Ho K, Gomes A . Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 2010; 95(7):1081-9. PMC: 2895031. DOI: 10.3324/haematol.2009.017178. View

Raggo C, Ruhl R, McAllister S, Koon H, Dezube B, Fruh K . Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res. 2005; 65(12):5084-95. DOI: 10.1158/0008-5472.CAN-04-2822. View

Ishibe N, Albitar M, Jilani I, Goldin L, Marti G, Caporaso N . CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. Blood. 2002; 100(3):1100-1. DOI: 10.1182/blood-2002-03-0938. View

10.

Xu X, Zhang X, Liu Y, Yang L, Huang S, Lu L . BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin. Oncotarget. 2016; 7(17):24436-54. PMC: 5029713. DOI: 10.18632/oncotarget.8332. View

11.

Konopleva M, Konoplev S, Hu W, Zaritskey A, Afanasiev B, Andreeff M . Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002; 16(9):1713-24. DOI: 10.1038/sj.leu.2402608. View

12.

Clark B, Keating A . Biology of bone marrow stroma. Ann N Y Acad Sci. 1995; 770:70-8. DOI: 10.1111/j.1749-6632.1995.tb31044.x. View

13.

Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta K . The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2007; 283(7):4283-94. DOI: 10.1074/jbc.M707465200. View

14.

Cui C, Wang P, Cui N, Song S, Liang H, Ji A . Sulfated polysaccharide isolated from the sea cucumber Stichopus japonicas promotes the SDF-1α/CXCR4 axis-induced NSC migration via the PI3K/Akt/FOXO3a, ERK/MAPK, and NF-κB signaling pathways. Neurosci Lett. 2016; 616:57-64. DOI: 10.1016/j.neulet.2016.01.041. View

15.

Jin L, Hope K, Zhai Q, Smadja-Joffe F, Dick J . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-74. DOI: 10.1038/nm1483. View

16.

Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H . Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol. 2004; 220(1-2):59-65. DOI: 10.1016/j.mce.2004.03.009. View

17.

Jung M, Rho J, Kim Y, Jung J, Jin Y, Ko Y . Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 2012; 32(2):209-21. DOI: 10.1038/onc.2012.37. View

18.

Chen Y, Lebrun J, Vale W . Regulation of transforming growth factor beta- and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci U S A. 1996; 93(23):12992-7. PMC: 24034. DOI: 10.1073/pnas.93.23.12992. View

19.

Chu C, Sheen Y, Cha S, Hu Y, Tan C, Chiu H . Induction of chemokine receptor CXCR4 expression by transforming growth factor-β1 in human basal cell carcinoma cells. J Dermatol Sci. 2013; 72(2):123-33. DOI: 10.1016/j.jdermsci.2013.06.011. View

20.

Azab A, Azab F, Quang P, Maiso P, Sacco A, Ngo H . FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. Clin Cancer Res. 2011; 17(13):4389-99. DOI: 10.1158/1078-0432.CCR-10-2772. View